Evidence map›Paper›PMID 25821840›Full record

ReviewOncoscience2015

The "virgin birth", polyploidy, and the origin of cancer.

Jekaterina Erenpreisa, Kristine Salmina, Anda Huna, Thomas R Jackson, Alejandro Vazquez-Martin, Mark S Cragg

Open access · hybridAbstract readReview
In one paragraph

Review in Oncoscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Nuclear destabilisation - a possible genesis of cancer?Biological reviews of the Cambridge Philosophical Society · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. The Digital World of Cytogenetic and Cytogenomic Web Resources.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  10. The New Era of Cancer Cytogenetics and Cytogenomics.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  11. Frontiers in cell and developmental biology · 2024
    Review
  12. Special Issue "Advances in Genome Regulation in Cancer".International journal of molecular sciences · 2023
    Article
  13. Review
  14. Article
  15. Spatial-Temporal Genome Regulation in Stress-Response and Cell-Fate Change.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Polyploidy as an Adaptation against Loss of Heterozygosity in Cancer.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jekaterina ErenpreisaLatvian Biomedical Research & Study Centre, Riga.
Kristine SalminaLatvian Biomedical Research & Study Centre, Riga.
Anda HunaLatvian Biomedical Research & Study Centre, Riga.
Thomas R JacksonFaculty Institute for Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, UK.
Alejandro Vazquez-MartinLatvian Biomedical Research & Study Centre, Riga.
Mark S CraggSouthampton University School of Medicine, Southampton, UK.
Latvian Biomedical Research and Study Centre · LVManchester Academic Health Science Centre · GBUniversity of Southampton · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, it has become clear that the complexity of cancer biology cannot fully be explained by somatic mutation and clonal selection. Meanwhile, data have accumulated on how cancer stem cells or stemloids bestow immortality on tumour cells and how reversible polyploidy is involved. Most recently, single polyploid tumour cells were shown capable of forming spheroids, releasing EMT-like descendents and inducing tumours in vivo. These data refocus attention on the centuries-old embryological theory of cancer. This review attempts to reconcile seemingly conflicting data by viewing cancer as a pre-programmed phylogenetic life-cycle-like process. This cycle is apparently initiated by a meiosis-like process and driven as an alternative to accelerated senescence at the DNA damage checkpoint, followed by an asexual syngamy event and endopolyploid-type embryonal cleavage to provide germ-cell-like (EMT) cells. This cycle is augmented by genotoxic treatments, explaining why chemotherapy is rarely curative and drives resistance. The logical outcome of this viewpoint is that alternative treatments may be more efficacious - either those that suppress the endopolyploidy-associated 'life cycle' or, those that cause reversion of embryonal malignant cells into benign counterparts. Targets for these opposing strategies are components of the same molecular pathways and interact with regulators of accelerated senescence.

Indexed as

accelerated senescencecancerembryonalityparthenogenesispolyploidy

Identifiers

PMID25821840
PMCPMC4341460
OpenAlexW146338168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.